Equities Analysts Issue Forecasts for Pfizer Inc.’s Q3 2025 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Stock analysts at Zacks Research dropped their Q3 2025 EPS estimates for Pfizer in a research report issued on Wednesday, May 22nd. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will post earnings per share of $0.72 for the quarter, down from their previous estimate of $0.75. The consensus estimate for Pfizer’s current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.58 EPS.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the business earned $1.23 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis.

PFE has been the subject of a number of other reports. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $35.86.

Pfizer Price Performance

NYSE:PFE opened at $28.88 on Friday. Pfizer has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $27.27 and a 200 day simple moving average of $27.96. The stock has a market capitalization of $163.65 billion, a PE ratio of -481.25, a P/E/G ratio of 1.16 and a beta of 0.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the fourth quarter worth about $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.